-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head to Head Contrast: Fresh Tracks Therapeutics (FRTX) and Its Rivals
Head to Head Contrast: Fresh Tracks Therapeutics (FRTX) and Its Rivals
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 276 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it contrast to its rivals? We will compare Fresh Tracks Therapeutics to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.
Volatility and Risk
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Get Fresh Tracks Therapeutics alerts:Profitability
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.07% | -37.03% |
Insider and Institutional Ownership
7.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 46.7% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all "Biological products, except diagnostic" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.Analyst Ratings
This is a summary of recent ratings and recommmendations for Fresh Tracks Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 873 | 3827 | 10681 | 159 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 133.90%. As a group, "Biological products, except diagnostic" companies have a potential upside of 81.42%. Given Fresh Tracks Therapeutics' higher possible upside, equities research analysts plainly believe Fresh Tracks Therapeutics is more favorable than its rivals.
Valuation and Earnings
This table compares Fresh Tracks Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.20 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -1.75 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 7 of the 10 factors compared.
About Fresh Tracks Therapeutics
(Get Rating)
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 276 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it contrast to its rivals? We will compare Fresh Tracks Therapeutics to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.
Fresh Track Treateutics(納斯達克代碼：FRTX-GET Rating)是除診斷外的生物製品行業的276家上市公司之一，但它與競爭對手有何不同？我們將根據機構所有權、股息、收益、分析師建議、盈利能力、風險和估值將Fresh Track Treateutics與相關公司進行比較。
Volatility and Risk
波動性和風險
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Fresh Track治療公司的貝塔係數為0.29，這表明其股價的波動性比標準普爾500指數低71%。相比之下，Fresh Track Treeutics的競爭對手的貝塔係數為0.75，這表明它們的平均股價波動性比標準普爾500指數低25%。
Profitability
盈利能力
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
下表比較了Fresh Track治療公司及其競爭對手的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.07% | -37.03% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 新奇軌道治療公司 | -453.11% | -133.55% | -108.52% |
| Fresh Track Treateutics競爭對手 | -4,576.34% | -104.07% | -37.03% |
Insider and Institutional Ownership
內部人與機構持股
Analyst Ratings
分析師評級
This is a summary of recent ratings and recommmendations for Fresh Tracks Therapeutics and its rivals, as reported by MarketBeat.com.
據MarketBeat.com報道，這是對Fresh Track治療公司及其競爭對手最近的評級和推薦的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 873 | 3827 | 10681 | 159 | 2.65 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 新奇軌道治療公司 | 0 | 0 | 0 | 0 | 不適用 |
| Fresh Track Treateutics競爭對手 | 873 | 3827 | 10681 | 159 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 133.90%. As a group, "Biological products, except diagnostic" companies have a potential upside of 81.42%. Given Fresh Tracks Therapeutics' higher possible upside, equities research analysts plainly believe Fresh Tracks Therapeutics is more favorable than its rivals.
Fresh Track治療公司目前的共識目標價為4.00美元，暗示潛在上漲133.90%。作為一個整體，“生物製品，除診斷”公司有81.42%的潛在上行空間。考慮到Fresh Track治療公司更高的可能上行空間，股票研究分析師顯然認為Fresh Track治療公司比其競爭對手更有利。
Valuation and Earnings
估值和收益
This table compares Fresh Tracks Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
此表比較了Fresh Track Treeutics及其競爭對手的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.20 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -1.75 |
| 總收入 | 淨收入 | 市盈率 | |
| 新奇軌道治療公司 | $400,000.00 | -3,947萬元 | -0.20 |
| Fresh Track Treateutics競爭對手 | 7.6719億美元 | 1.4684億美元 | -1.75 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Fresh Track治療公司的競爭對手比Fresh Track治療公司有更高的收入和收益。Fresh Track治療公司的市盈率高於競爭對手，這表明它目前的價格高於行業內的其他公司。
Summary
摘要
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 7 of the 10 factors compared.
Fresh Track治療公司的競爭對手在比較的10個因素中有7個擊敗了Fresh Track治療公司。
About Fresh Tracks Therapeutics
關於Fresh Track治療公司
(Get Rating)
(獲取評級)
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Fresh Track治療公司是一家臨牀階段的製藥公司，致力於開發各種處方療法，用於治療美國的自身免疫、炎症和其他令人衰弱的疾病。該公司開發的產品包括：已完成治療原發性腋窩多汗症的第三階段臨牀試驗的索吡溴銨；用於治療自身免疫和炎症性疾病的口服DYRK1A抑制劑BBI-02；以及用於潛在治療自體炎症和罕見遺傳性疾病的幹擾素基因共價刺激物BBI-10，以及下一代激酶抑制劑。它與Carna Biosciences，Inc.，Voronoi Inc.，Bodor實驗室，Inc.和Nicholas S.Bodor博士以及Anges，Inc.簽訂了許可和合作協議。該公司前身為Brickell Biotech，Inc.，並於2022年9月更名為Fresh Track治療公司。Fresh Track治療公司成立於2009年，總部設在科羅拉多州博爾德市。
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受新聞和評級的新軌道治療每日-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對Fresh Track Treeutics和相關公司的評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧